echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > J Thromb Haemost: Recombinant human soluble thrombosis-regulated protein sepsis efficacy and safety in patients with sepsis-related clotting disorders

    J Thromb Haemost: Recombinant human soluble thrombosis-regulated protein sepsis efficacy and safety in patients with sepsis-related clotting disorders

    • Last Update: 2020-06-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The efficacy and safety of the recombinant human soluble thrombosis-regulated protein (rhsTM) has not been clearly proven and its effects may depend on the presence or absence of sepsis-related clotting disease (SAC)Recently, the authoritative journal Journal of Thrombosis and Haemostasis published a research article, the system evaluation and meta-analysis is designed to assess the efficacy and safety of rhsTM in SAC patients, sAC is determined by high international standardization rates and low platelet countsresearchers searched the EMBASE, MEDLINE, CENTRAL, and Clinicaltrial.gov databases to determine a randomized controlled trial (RCT) comparing rhsTM with patients with placebo or untreated sepsisThe outcome was 28 days of mortality and the safe outcome was hemorrhageresearchers included three RCTs and 1,633 patientsPatients with SAC had a higher 28-day mortality rate (risk ratio of 1.32; 95% confidence interval (CI) 1.06-1.64 compared to patients without SACRhsTM treatment significantly reduced the patient's mortality rate by 28 days compared to patients with placebo or untreated SAC (RR 0.80; 95% CI is 0.65-0.98), but for patients without SAC (RR 1.17; 95% CI is 0.82-1.67) or the entire study population (RR is 0.88; 95% CI is 0.74-1.04) no significant effectThe whole population (RR is 1.25; 95% CI is 0.80-1.96), SAC patients (RR is 0.94; 95% CI is 0.45-1.95) and patients without SAC (RR 2.26; In 95% CI was 0.95-5.35), there was no significant difference in the incidence of haemorrhage between rhsTM and the control drug, sAC is associated with a higher 28-day mortality rate in patients with sepsisThe use of rhsTM reduced the 28-day mortality rate in SAC patients, but did not reduce the mortality rate in patients without SAC
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.